Literature DB >> 16968717

Gemcitabine-induced thrombotic microangiopathy: a systematic review.

Hassane Izzedine, Corinne Isnard-Bagnis, Vincent Launay-Vacher, Lucille Mercadal, Isabelle Tostivint, Olivier Rixe, Isabelle Brocheriou, Edward Bourry, Svetlana Karie, Samir Saeb, Nadine Casimir, Bertrand Billemont, Gilbert Deray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16968717     DOI： 10.1093/ndt/gfl507

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  30 in total

Review 1.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

2.  [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].

Authors:  M J Behne; U Hauswirth; A Menz; N Brüllke; U Müllerleile; I Moll
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

Review 3.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

4.  ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.

Authors:  Peter G Bittar; Myles S Nickolich; Oluwatoyosi A Onwuemene
Journal:  J Clin Apher       Date:  2017-09-23       Impact factor: 2.821

Review 5.  Drug-induced glomerular disease: direct cellular injury.

Authors:  Glen S Markowitz; Andrew S Bomback; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-10       Impact factor: 8.237

6.  Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.

Authors:  Jeanne Allard; Mathilde Bonnet; Lucie Laurent; Mohamed Bouattour; Marie-Pauline Gagaille; Vincent Leclerc
Journal:  Eur J Clin Pharmacol       Date:  2022-05-04       Impact factor: 2.953

7.  Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.

Authors:  David S Hong; Goldy C George; Eucharia C Iwuanyanwu; Bahareh Tavana; Gerald S Falchook; Sarina A Piha-Paul; Jennifer J Wheler; Reena H Mistry; Xiudong Lei; Razelle Kurzrock
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-02       Impact factor: 4.553

8.  A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Authors:  David S Hong; Jennifer Hsing Choe; Aung Naing; Jennifer J Wheler; Gerald S Falchook; Sarina Piha-Paul; Stacy L Moulder; Goldy C George; Jonathan M Choe; Lewis C Strauss; Gary E Gallick; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2012-11-20       Impact factor: 3.850

9.  Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.

Authors:  Maximilien Grall; Florence Daviet; Noémie Jourde Chiche; François Provot; Claire Presne; Jean-Philippe Coindre; Claire Pouteil-Noble; Alexandre Karras; Dominique Guerrot; Arnaud François; Ygal Benhamou; Agnès Veyradier; Véronique Frémeaux-Bacchi; Paul Coppo; Steven Grangé
Journal:  BMC Nephrol       Date:  2021-07-21       Impact factor: 2.388

10.  Digital ischemic events related to gemcitabine: Report of two cases and a systematic review.

Authors:  Cvetka Grasic Kuhar; Tanja Mesti; Branko Zakotnik
Journal:  Radiol Oncol       Date:  2010-05-03       Impact factor: 2.991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.